decitabine + BP1002

Decitabine + BP1002 is an investigational combination therapy under clinical evaluation for the treatment of refractory or relapsed acute myeloid leukemia (AML). Decitabine is a pyrimidine nucleoside analogue and hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferases, leading to global DNA hypomethylation, reactivation of silenced genes, and induction of cell differentiation or apoptosis. It is approved for myelodysplastic syndromes (MDS) and used off-label in AML. BP1002 is a liposomal antisense oligonucleotide designed to target Bcl-2 mRNA, thereby reducing expression of the anti-apoptotic B-cell lymphoma 2 protein (Bcl‑2) implicated in cancer cell survival and resistance to therapy. By targeting Bcl-2 at the mRNA level rather than the protein itself, BP1002 may overcome resistance mechanisms seen with current Bcl-2 inhibitors such as venetoclax. The combination aims to provide therapeutic benefit in patients who have failed standard therapies including venetoclax-based regimens[1][3][4][5][6].

Brand names

DacogenInaqoviInqovi

Other names

liposomal Bcl-2 antisense oligodeoxynucleotide (for BP1002)